Active Clinical Trials at OOS

Tumor site:

Lung

Description:

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1

Available at:

Our Salem Office

More info:

See this trial on ClinicalTrials.gov »

Tumor site:

Lung

Description:

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1

Available at:

Our Salem Office

More info:

See this trial on ClinicalTrials.gov »

Tumor site:

Hematologic (MDS, CMML, AML)

Description:

A Multi-phase, Dose-Escalation followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)

Available at:

Our Salem Office

More info:

See this trial on ClinicalTrials.gov »

Tumor site:

Breast

Description:

Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I)

Available at:

Our Salem Office, Our McMinnville Office, Our Silverton Office, Our Woodburn Office

More info:

See this trial on ClinicalTrials.gov »

Tumor site:

Solid Tumors

Description:

Tumor methylation scores will be quantified at baseline across all tumor types to establish the clinical limit of detection of the assay. Associations between baseline tumor methylation score and PFS, OS, and disease control rate will be examined across therapeutic regimens and cancer types to test the hypothesis that the TMS is prognostic of outcome.

Available at:

Our Salem Office, Our McMinnville Office, Our Silverton Office, Our Woodburn Office

Tumor site:

Breast

Description:

Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-Positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence- A Global, Multicenter, Randomized, Open-Label Phase 3 study

Available at:

Our Salem Office

More info:

See this trial on ClinicalTrials.gov »

Tumor site:

Lung

Description:

TEMPUS GEMINI (TP-CA-002) NSCLC SURVEILLANCE STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Non-Small Cell Lung Cancer (NSCLC)

Available at:

Our Salem Office, Our McMinnville Office, Our Silverton Office, Our Woodburn Office

More info:

See this trial on ClinicalTrials.gov »

Tumor site:

Colorectal Cancer

Description:

A Phase I/Ib global, multicenter, open-label umbrella study evaluating the safety and efficacy of targeted therapies in subpopulations of patients with metastatic colorectal cancer

Available at:

Our Salem Office

More info:

See this trial on ClinicalTrials.gov »

Tumor site:

Lung (NSCLC)

Description:

Phase 3 Trial of MRTX849 Plus Pembrolizumab for NSCLC With KRAS G12C Mutation (KRYSTAL-7)

Available at:

Our Salem Office

More info:

See this trial on ClinicalTrials.gov »

Tumor site:

Breast; Lung

Description:

Collection of Biological Specimens and Associated Health Information for Secondary Research in Future Studies

Available at:

Our Salem Office, Our McMinnville Office, Our Silverton Office, Our Woodburn Office

More info:

See this trial on ClinicalTrials.gov »